Kevin H Kensler1,2, A Heather Eliassen3,4, Bernard A Rosner4,5, Susan E Hankinson3,4,6, Myles Brown7, Rulla M Tamimi3,4. 1. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. kkensler@mail.harvard.edu. 2. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA. kkensler@mail.harvard.edu. 3. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA. 4. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA. 5. Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, 02115, USA. 6. Department of Biostatistics and Epidemiology, University of Massachusetts School of Public Health and Health Sciences, Amherst, MA, 01003, USA. 7. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
Abstract
PURPOSE: Higher levels of circulating sex steroid hormones are associated with increased breast cancer risk, though their association with prognosis remains unclear. We evaluated the association between circulating sex hormone levels and breast cancer survival in two large cohorts. METHODS: We evaluated this association among 2073 breast cancer cases from the Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII) cohorts. Women in this analysis provided a blood sample in 1989-1990 (NHS) or in 1996-1999 (NHSII) and were subsequently diagnosed with breast cancer. Levels of estradiol (postmenopausal women only), testosterone, dehydroepiandrosterone-sulfate (DHEAS), and sex hormone-binding globulin (SHBG) were measured in plasma. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for survival, adjusting for patient and tumor characteristics. RESULTS: A total of 639 deaths and 160 breast cancer deaths occurred over follow-up through 2015. Compared to women in the lowest quartile, postmenopausal women in the highest quartile of estradiol experienced a 1.43-fold overall mortality rate (HR 1.43, 95% CI 1.03-1.97, P-trend = 0.04) and a nonsignificantly higher breast cancer mortality rate (HR 1.50, 95% CI 0.75-2.98, P-trend = 0.12). Higher DHEAS levels were nonsignificantly associated with better overall survival (HRQ4vsQ1=0.79, 95% CI 0.57-1.10, P-trend = 0.05), though not with breast cancer survival. No associations were observed between testosterone or SHBG and survival. CONCLUSIONS: Pre-diagnostic postmenopausal circulating estradiol levels were modestly associated with worse survival among breast cancer patients. Further studies should evaluate whether circulating hormone levels at diagnosis predict cancer prognosis or treatment response.
PURPOSE: Higher levels of circulating sex steroid hormones are associated with increased breast cancer risk, though their association with prognosis remains unclear. We evaluated the association between circulating sex hormone levels and breast cancer survival in two large cohorts. METHODS: We evaluated this association among 2073 breast cancer cases from the Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII) cohorts. Women in this analysis provided a blood sample in 1989-1990 (NHS) or in 1996-1999 (NHSII) and were subsequently diagnosed with breast cancer. Levels of estradiol (postmenopausal women only), testosterone, dehydroepiandrosterone-sulfate (DHEAS), and sex hormone-binding globulin (SHBG) were measured in plasma. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for survival, adjusting for patient and tumor characteristics. RESULTS: A total of 639 deaths and 160 breast cancer deaths occurred over follow-up through 2015. Compared to women in the lowest quartile, postmenopausal women in the highest quartile of estradiol experienced a 1.43-fold overall mortality rate (HR 1.43, 95% CI 1.03-1.97, P-trend = 0.04) and a nonsignificantly higher breast cancer mortality rate (HR 1.50, 95% CI 0.75-2.98, P-trend = 0.12). Higher DHEAS levels were nonsignificantly associated with better overall survival (HRQ4vsQ1=0.79, 95% CI 0.57-1.10, P-trend = 0.05), though not with breast cancer survival. No associations were observed between testosterone or SHBG and survival. CONCLUSIONS: Pre-diagnostic postmenopausal circulating estradiol levels were modestly associated with worse survival among breast cancerpatients. Further studies should evaluate whether circulating hormone levels at diagnosis predict cancer prognosis or treatment response.
Entities:
Keywords:
Breast cancer; DHEAS; Estradiol; Prognosis; SHBG; Testosterone
Authors: A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo Journal: Br J Cancer Date: 2004-01-12 Impact factor: 7.640
Authors: Alleigh G Wiggs; Justin K Chandler; Aynur Aktas; Susan J Sumner; Delisha A Stewart Journal: Front Endocrinol (Lausanne) Date: 2021-09-20 Impact factor: 5.555